Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

xellia pharmaceuticals aps - colistimethatnatrium - pulver til injektions-/infusionsvæske, opløsning - 1.000.000 ie

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

oba-pharma aps - benzocain, myrratinktur - opløsning til tandkød - 5+75 mg/g

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

infectopharm gmbh - fosfomycinnatrium - pulver til infusionsvæske, opløsning - 40 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

cipla europe nv - methotrexat - tabletter - 2,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

zambon s.p.a. - colistimethatnatrium - pulver til infusionsvæske, opløsning - 1.000.000 ie

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

aspen pharma trading limited - lidocainhydrochlorid - injektionsvæske, opløsning - 20 mg/ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastiske midler - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

plethora pharma solutions limited - lidocain, prilocaine - for tidlig sædafgang - anæstesiologi - senstend er indiceret til behandling af primær tidlig sædafgang hos voksne mænd.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfom, mantelcelle - antineoplastiske midler - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).